ENXTPA:ALCOR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Biocorp Production designs, develops, and manufactures medical devices and drug delivery systems in France.


Snowflake Analysis

Exceptional growth potential and good value.

Share Price & News

How has Biocorp Production's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALCOR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.7%

ALCOR

-11.5%

FR Medical Equipment

8.7%

FR Market


1 Year Return

47.2%

ALCOR

42.8%

FR Medical Equipment

-2.4%

FR Market

Return vs Industry: ALCOR exceeded the French Medical Equipment industry which returned 42.8% over the past year.

Return vs Market: ALCOR exceeded the French Market which returned -2.4% over the past year.


Shareholder returns

ALCORIndustryMarket
7 Day-4.7%-11.5%8.7%
30 Day7.4%-1.9%15.9%
90 Day26.4%35.6%1.3%
1 Year47.2%47.2%42.8%42.8%-0.7%-2.4%
3 Year52.6%52.6%43.9%42.1%11.2%2.2%
5 Yearn/a144.9%139.2%31.1%14.3%

Price Volatility Vs. Market

How volatile is Biocorp Production's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biocorp Production undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ALCOR (€16.05) is trading below our estimate of fair value (€135.49)

Significantly Below Fair Value: ALCOR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ALCOR is good value based on its PE Ratio (-48.8x) compared to the Medical Equipment industry average (44.3x).

PE vs Market: ALCOR is good value based on its PE Ratio (-48.8x) compared to the French market (15.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALCOR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALCOR is overvalued based on its PB Ratio (213x) compared to the FR Medical Equipment industry average (2.7x).


Next Steps

Future Growth

How is Biocorp Production forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

48.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALCOR's forecast earnings growth (48.4% per year) is above the savings rate (0.6%).

Earnings vs Market: ALCOR's earnings (48.4% per year) are forecast to grow faster than the French market (13.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ALCOR's revenue (36.1% per year) is forecast to grow faster than the French market (4.1% per year).

High Growth Revenue: ALCOR's revenue (36.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALCOR's Return on Equity is forecast to be very high in 3 years time (69%).


Next Steps

Past Performance

How has Biocorp Production performed over the past 5 years?

-2.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALCOR has high quality earnings.

Growing Profit Margin: ALCOR became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ALCOR has become profitable over the past 5 years, growing earnings by -2.7% per year.

Accelerating Growth: ALCOR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ALCOR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-2%).


Return on Equity

High ROE: Whilst ALCOR's Return on Equity (308.66%) is outstanding, this metric is skewed due to their high level of debt.


Next Steps

Financial Health

How is Biocorp Production's financial position?


Financial Position Analysis

Short Term Liabilities: ALCOR's short term assets (€6.6M) exceed its short term liabilities (€4.6M).

Long Term Liabilities: ALCOR's short term assets (€6.6M) exceed its long term liabilities (€3.2M).


Debt to Equity History and Analysis

Debt Level: ALCOR's debt to equity ratio (1659.9%) is considered high.

Reducing Debt: ALCOR's debt to equity ratio has increased from 696.7% to 1659.9% over the past 5 years.

Debt Coverage: ALCOR's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: ALCOR's interest payments on its debt are well covered by EBIT (5.5x coverage).


Balance Sheet


Next Steps

Dividend

What is Biocorp Production's current dividend yield, its reliability and sustainability?

4.66%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALCOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALCOR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALCOR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALCOR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALCOR's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

15.4yrs

Average management tenure


CEO

Eric Dessertenne

0.50

Tenure

Mr. Eric Dessertenne serves as Chief Executive Officer at Biocorp Production since December 2019. He had been Chief Operating Officer of Biocorp Production since December 9, 2016 until December 2019. Mr. D ...


Leadership Team

NamePositionTenureCompensationOwnership
Jacques Gardette
Founder & Chairman5.08yrs€28.87k0.0049% 3.2k
Eric Dessertenne
Chief Executing Officer0.50yrno datano data
Stéphane Chabanais
Administrative & Financial Director15.42yrsno datano data
Sylvaine Dessard
Marketing & Communication Directorno datano datano data
Alain Marcoz
Head of Software R&Dno datano datano data
Thierry Guillemaut
Head of Productionno datano datano data
Daniel Aneas
Head of Product R&Dno datano datano data
Patrick Quéro
Head of Quality & Regulatory Affairsno datano datano data

15.4yrs

Average Tenure

Experienced Management: ALCOR's management team is seasoned and experienced (15.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jacques Gardette
Founder & Chairman5.08yrs€28.87k0.0049% 3.2k
Jean-Yves Berthon
Independent Director5.08yrsno datano data
Lutz Heinemann
Member of Scientific Advisory Boardno datano datano data
Stephane Legastelois
Director5.08yrsno datano data
Emilie Gardette
Director5.08yrsno datano data
Julien Gardette
Director5.08yrsno datano data
Jean-Pierre Riveline
Member of Scientific Advisory Boardno datano datano data
Pauline Schaepelynck-Belicar
Member of Scientific Advisory Boardno datano datano data

5.1yrs

Average Tenure

Experienced Board: ALCOR's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biocorp Production's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biocorp Production
  • Ticker: ALCOR
  • Exchange: ENXTPA
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €66.245m
  • Shares outstanding: 4.13m
  • Website: https://biocorpsys.com

Number of Employees


Location

  • Biocorp Production
  • Parc Technologique
  • Lavaur-la-BEchade
  • Issoire
  • Auvergne
  • 63500
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALCORENXTPA (Euronext Paris)YesOrdinary SharesFREURJul 2015

Biography

Biocorp Production designs, develops, and manufactures medical devices and drug delivery systems in France. The company provides connected medical devices, including Inspair, a smart cap to monitor inhalers and assesses the usage of the device; Mallya, a smart cap for pen injectors that captures injection data; Onejet, a motor driven disposable auto-injector, which designs to deliver viscosity products; Datapen, a motor driven pen injector; and Injay that collects essential information, such as injection completed, time and date, type of drug, batch number, and expiration date. It also offers pharmaceutical devices, such as Newguard, a safety device compatible with various sizes of needles prefilled syringes; Biopass, a reconstitution system; and closure systems. The company was founded in 2004 and is headquartered in Issoire, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/06 07:12
End of Day Share Price2020/06/05 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.